Marc Abrams

Company: Carbon Biosciences

Job title: Chief Scientific Officer

Seminars:

Beyond AAV: Unlocking the Potential of Gene Therapy with Novel Parvovirus Vectors 4:15 pm

New recombinant non-AAV parvovirus vectors designed to overcome many of the challenges associated with AAV vectors CBN-1100 is a vector derived from a natural parvovirus species featuring higher cargo capacity compared to AAV, potency in diverse cell types, a compelling liver de-targeted distribution profile, high manufacturability and scalability, and minimal human seroprevalence The pharmacological attributes…Read more

day: Conference Day Two